BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10537332)

  • 1. Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients.
    Thomas PA; Kirschmann DA; Cerhan JR; Folberg R; Seftor EA; Sellers TA; Hendrix MJ
    Clin Cancer Res; 1999 Oct; 5(10):2698-703. PubMed ID: 10537332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
    Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
    Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of epithelial markers and acquisition of vimentin expression in adriamycin- and vinblastine-resistant human breast cancer cell lines.
    Sommers CL; Heckford SE; Skerker JM; Worland P; Torri JA; Thompson EW; Byers SW; Gelmann EP
    Cancer Res; 1992 Oct; 52(19):5190-7. PubMed ID: 1382837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
    Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
    Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of epithelial-mesenchymal transition in breast cancer.
    Fuchs IB; Lichtenegger W; Buehler H; Henrich W; Stein H; Kleine-Tebbe A; Schaller G
    Anticancer Res; 2002; 22(6A):3415-9. PubMed ID: 12530097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells.
    Willipinski-Stapelfeldt B; Riethdorf S; Assmann V; Woelfle U; Rau T; Sauter G; Heukeshoven J; Pantel K
    Clin Cancer Res; 2005 Nov; 11(22):8006-14. PubMed ID: 16299229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
    Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic determinants of uveal melanoma metastatic phenotype: role of intermediate filaments as predictive markers.
    Hendrix MJ; Seftor EA; Seftor RE; Gardner LM; Boldt HC; Meyer M; Pe'er J; Folberg R
    Lab Invest; 1998 Feb; 78(2):153-63. PubMed ID: 9484713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.
    Mylona EE; Alexandrou PT; Giannopoulou IA; Rafailidis PI; Markaki S; Keramopoulos A; Nakopoulou LL
    Cancer Detect Prev; 2006; 30(2):111-7. PubMed ID: 16632244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
    Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
    J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic significance of coexpression of intermediate filaments in fine needle aspirates of human tumors.
    Domagala W; Weber K; Osborn M
    Acta Cytol; 1988; 32(1):49-59. PubMed ID: 2447723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
    Voduc D; Nielsen TO; Cheang MC; Foulkes WD
    Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signal transducer and activator of transcription-5 activation and breast cancer prognosis.
    Nevalainen MT; Xie J; Torhorst J; Bubendorf L; Haas P; Kononen J; Sauter G; Rui H
    J Clin Oncol; 2004 Jun; 22(11):2053-60. PubMed ID: 15169792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer.
    Laakso M; Tanner M; Nilsson J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Bergh J; Isola J
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4185-91. PubMed ID: 16857790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of luminal and basal cytokeratins in human breast carcinoma.
    Abd El-Rehim DM; Pinder SE; Paish CE; Bell J; Blamey RW; Robertson JF; Nicholson RI; Ellis IO
    J Pathol; 2004 Jun; 203(2):661-71. PubMed ID: 15141381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.